\
&
Contact us
\
&
Contact us
Published on | 1 year ago
ProgrammesThe European Commission and the Republic of Korea (South Korea) have concluded the association negotiations to Horizon Europe. The association agreement will allow South Korean researchers to participate in Pillar 2 of Horizon Europe on the same terms as Member States. The signing of the association agreement is expected to take place in the second half of 2024, pending the completion of all necessary ratification procedures on both sides. This will enable South Korea's participation in Horizon Europe as associated country as of 2025. See this press release for more information.
More information on the association process to Horizon Europe of other third countries can also be found in this infosheet on International Cooperation.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
